stock-detail (TPIV)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/19/2017 06:19 am

4/19/2017 06:19 am

4/19/2017 06:19 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment

3/24/2017 12:03 pm

[Marketwired] - NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

3/22/2017 03:00 pm

[PR Newswire] - JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TAPIMMUNE INC Financials

3/18/2017 05:00 pm

TapImmune Provides Year End 2016 Corporate and Clinical Update

3/14/2017 08:00 pm

[PR Newswire] - TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

3/14/2017 01:01 pm

[PR Newswire] - JACKSONVILLE, Fla., March 14, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS). If successful, TapImmune's vaccine may replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women. "This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication," said Dr. Glynn Wilson, chairman and CEO of TapImmune.

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

3/8/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., March 8, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

2/15/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Feb. 15, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced its lead cancer vaccine candidate, TPIV 200, received a positive recommendation from an independent Data Safety Monitoring Board (DSMB) to continue dosing triple-negative breast cancer (TNBC) patients in an ongoing Phase 2 clinical trial.

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

2/9/2017 01:03 pm

[PR Newswire] - Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation JACKSONVILLE, Fla., Feb. 9, 2017 /PRNewswire/ -- TapImmune, ...

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

2/9/2017 01:03 pm

[CNW Group] - TapImmune, Inc. Presentation Now Available for On-Demand Viewing

TapImmune Expands Intellectual Property On PolyStartâ„¢ Platform For Use In Next-Generation T-Cell Vaccines

2/7/2017 02:01 pm

[PR Newswire] - The patent expands upon the company's intellectual property for its proprietary PolyStartâ„¢ antigen expression technology, which elevates the expression of T-cell antigenic epitopes for use in next-generation vaccines for cancer or infectious diseases. The patent claims cover the use of PolyStart to express Class I and II antigenic peptides of HER2, an important cell surface protein that is overexpressed in more than 20 percent of all breast cancer patients.

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

2/2/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Feb. 2, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company's multi-epitope T-cell vaccine targeting folate receptor alpha. The manufactured vaccine product will be used to supply an ongoing Phase 2 study of TPIV 200 for the treatment of platinum-sensitive ovarian cancer, as well as a planned Phase 2 study sponsored by the Mayo Clinic for treating triple-negative breast cancer.

TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2

1/30/2017 01:03 pm

[PR Newswire] - Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com JACKSONVILLE, Fla., Jan. 30, 2017 /PRNewswire/ -- TapImmune, ...